Summary

Pharmaceutical companies are urging the Trump administration and EU officials to exclude medical goods from new tariffs, warning of higher drug costs and reduced access to life-saving medicines.

Industry leaders argue tariffs would contradict U.S. healthcare priorities and are negotiating tax breaks for expanded domestic production.

Companies like Novo Nordisk and Merck may face short-term impacts but are investing in U.S. manufacturing. Analysts say drug price hikes could burden Medicare and Medicaid.

The industry’s response from Washington remains unclear, while EU officials have yet to announce countermeasures.